Literature DB >> 19331200

Concomitant overexpression of heat-shock protein 70 and HLA class-I in hepatitis C virus-related hepatocellular carcinoma.

Shin Yoshida1, Shoichi Hazama, Kazuhisa Tokuno, Kazuhiko Sakamoto, Motonari Takashima, Takao Tamesa, Toshihiko Torigoe, Noriyuki Sato, Masaaki Oka.   

Abstract

BACKGROUND: Human leukocyte antigen (HLA) class I expression is reportedly frequently reduced in cancer. We examined heat-shock protein (HSP) expression in hepatocellular carcinoma (HCC). PATIENTS AND METHODS: HCV-related HCC was examined in 73 patients who had undergone hepatectomy, and the relationship between HSP70 and HLA class I expressions, clinicopathological factors and survival was evaluated.
RESULTS: Immunohistochemically positive results for HSP70 and HLA class I were seen in 67 (92%) and 43 cases (59%), respectively, while 38 patients (52%) were positive for both. Increased HSP70 immunoreactivity was significantly associated with high histological grade of tumor differentiation (p = 0.0179), whereas reduced HLA class I immunoreactivity was significantly associated with large tumor size (p = 0.0082). No differences were apparent between disease-free and overall survival in regard to expression levels.
CONCLUSION: These results suggest that HSP70 expression may be related to tumor differentiation and HLA class I loss may occur with tumor growth in HCV-related HCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19331200

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial.

Authors:  Hiroto Matsui Matsui; Shoichi Hazama; Masao Nakajima; Ming Xu; Satoshi Matsukuma; Yukio Tokumitsu; Yoshitaro Shindo; Shinobu Tomochika; Shin Yoshida; Michihisa Iida; Nobuaki Suzuki; Shigeru Takeda; Shigefumi Yoshino; Tomio Ueno; Masaaki Oka; Hiroaki Nagano
Journal:  Cancer Immunol Immunother       Date:  2020-10-19       Impact factor: 6.968

2.  Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis.

Authors:  Anupam Bishayee; Abhijeet Waghray; Kendra F Barnes; Thomas Mbimba; Deepak Bhatia; Malay Chatterjee; Altaf S Darvesh
Journal:  Pharm Res       Date:  2010-04-20       Impact factor: 4.200

3.  Proteome changes of lungs artificially infected with H-PRRSV and N-PRRSV by two-dimensional fluorescence difference gel electrophoresis.

Authors:  Shuqi Xiao; Qiwei Wang; Jianyu Jia; Peiqing Cong; Delin Mo; Xiangchun Yu; Limei Qin; Anning Li; Yuna Niu; Kongju Zhu; Xiaoying Wang; Xiaohong Liu; Yaosheng Chen
Journal:  Virol J       Date:  2010-05-26       Impact factor: 4.099

4.  Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.

Authors:  Nobuaki Suzuki; Shoichi Hazama; Haruo Iguchi; Kazuhiro Uesugi; Hiroaki Tanaka; Kosei Hirakawa; Atsushi Aruga; Takashi Hatori; Hidenobu Ishizaki; Yuzo Umeda; Toshiyoshi Fujiwara; Tetsuya Ikemoto; Mitsuo Shimada; Kazuhiko Yoshimatsu; Ryoichi Shimizu; Hiroto Hayashi; Koichiro Sakata; Hiroko Takenouchi; Hiroto Matsui; Yoshitaro Shindo; Michihisa Iida; Yasunobu Koki; Hideki Arima; Hiroyuki Furukawa; Tomio Ueno; Shigefumi Yoshino; Yusuke Nakamura; Masaaki Oka; Hiroaki Nagano
Journal:  Cancer Sci       Date:  2016-12-19       Impact factor: 6.716

5.  HIV and HCV augments inflammatory responses through increased TREM-1 expression and signaling in Kupffer and Myeloid cells.

Authors:  Jinhee Hyun; Robert S McMahon; Anna L Lang; Jasmine S Edwards; Alejandro Dmitar Badilla; Morgan E Greene; Geoffrey W Stone; Suresh Pallikkuth; Mario Stevenson; Derek M Dykxhoorn; Shyam Kottilil; Savita Pahwa; Emmanuel Thomas
Journal:  PLoS Pathog       Date:  2019-07-01       Impact factor: 6.823

6.  Higher human lymphocyte antigen class I expression in early-stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes.

Authors:  Yu Akazawa; Daisuke Nobuoka; Mari Takahashi; Toshiaki Yoshikawa; Manami Shimomura; Shoichi Mizuno; Toshiyoshi Fujiwara; Yasunari Nakamoto; Tetsuya Nakatsura
Journal:  Cancer Sci       Date:  2019-05-18       Impact factor: 6.716

7.  Identification of a Promiscuous Epitope Peptide Derived From HSP70.

Authors:  Hiroto Matsui; Shoichi Hazama; Koji Tamada; Keiko Udaka; Atsushi Irie; Yasuharu Nishimura; Tomoya Miyakawa; Shun Doi; Masao Nakajima; Shinsuke Kanekiyo; Yukio Tokumitsu; Yoshitaro Shindo; Shinobu Tomochika; Shin Yoshida; Michihisa Iida; Nobuaki Suzuki; Shigeru Takeda; Shigeru Yamamoto; Shigefumi Yoshino; Tomio Ueno; Hiroaki Nagano
Journal:  J Immunother       Date:  2019-09       Impact factor: 4.456

Review 8.  Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy.

Authors:  Shoichi Hazama; Koji Tamada; Yoshiyuki Yamaguchi; Yutaka Kawakami; Hiroaki Nagano
Journal:  Ann Gastroenterol Surg       Date:  2018-06-22

9.  A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial.

Authors:  Masao Nakajima; Shoichi Hazama; Koji Tamada; Keiko Udaka; Yasunobu Kouki; Toshinari Uematsu; Hideki Arima; Akira Saito; Shun Doi; Hiroto Matsui; Yoshitaro Shindo; Satoshi Matsukuma; Shinsuke Kanekiyo; Yukio Tokumitsu; Shinobu Tomochika; Michihisa Iida; Shin Yoshida; Yuki Nakagami; Nobuaki Suzuki; Shigeru Takeda; Shigeru Yamamoto; Shigefumi Yoshino; Tomio Ueno; Hiroaki Nagano
Journal:  Cancer Immunol Immunother       Date:  2020-03-26       Impact factor: 6.968

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.